Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Effect of comorbid pathology and its nosologic forms on annexin A5 levels in patients with SARS-COV-2-associated viral pneumonia
https://doi.org/10.33667/2078-5631-2024-4-60-63
Abstract
Purpose. To evaluate the effect of comorbidity on annexin A5 levels in patients with SARS-CоV-2 associated viral pneumonia.
Materials and Methods. We examined 90 patients diagnosed with coronavirus infection COVID-19 (virus identified), who were treated as inpatients in an infectious disease hospital. According to the results of computed tomography of the chest organs, 76 (84.4 %) patients had III degree of lung lesions, 14 (15.6 %) – IV degree. 84.4 % of patients were comorbid. The level of annexin A5 (ng/ml) in serum was studied by enzyme immunoassay method using ELISA Kit for Annexin A5 immunoenzyme reaction analyzer, produced by Cloud-Clone Corp. (USA). Statistical processing of the data was performed using the SPSS 26.0 program package.
Results of the study. 84,4 % of patients with SARS-CоV-2 associated pneumonia had significant cardiovascular, pulmonary or endocrine pathology. 50 % of the subjects had type II diabetes mellitus. Annexin A5 levels were statistically significantly higher in comorbid patients than in patients without comorbidities. The level of annexin A5 in those with multiple comorbidities was significantly higher than in those with 1–2 comorbidities. A direct correlation of moderate strength between the level of annexin A5 and the number of pathologic conditions present in the patient was revealed (0,437, p<0,001).
Conclusion: The obtained results indicate the necessity to take into account the presence of comorbidity and its nosologic forms when studying apoptotic processes in patients with SARS-CоV-2-associated pneumonia.
About the Authors
A. Sh. Kurmaeva
Astrakhan State Medical University
Russian Federation
Russian Federation
Kurmaeva Asiya Sh., postgraduate student, Dept of Internal Medicine, Faculty of Pediatrics
Astrakhan
T. V. Prokofieva
Astrakhan State Medical University
Russian Federation
Russian Federation
Prokofieva Tatyana V., PhD Med, associate professor, Dept of Internal Medicine, Faculty of Pediatrics
Astrakhan
O. S. Polunina
Astrakhan State Medical University
Russian Federation
Russian Federation
Polunina Olga S., DM Sci (habil.), head of Dept of Internal Medicine, Faculty of Pediatrics
Astrakhan
E. A. Polunina
Astrakhan State Medical University
Russian Federation
Russian Federation
Polunina Ekaterina A., DM Sci (habil.), professor, Dept of Internal Medicine, Faculty of Pediatrics
Astrakhan
References
1. Drapkina O. M., Shutov A. M., Efremova E. V. Comorbidity, multimorbidity, and dual diagnosis: synonyms or different concepts? Cardiovascular therapy and prevention. 2019; 18(2): 65–69.
2. Vertkin AL. Comorbidity: history, recent views, prevention and treatment. Cardiovascular Therapy and Prevention. 2015; 14(2): 74–9.
3. Oganov R. G., Denisov I. N., Simanenkov V. I., et al. Сomorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017; 16(6): 5–56.
4. Sharma A., Ahmad Farouk I., Lal S. K. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021; 13(2): 202. doi: 10.3390/v13020202.
5. Laine C., Moyer D. V., Cotton D. COVID-19: Challenging Clinical Questions. Ann Intern Med. 2022; 175(2): 276–277. doi: 10.7326/M21–4611. Epub 2021 Dec 14.
6. Ejaz H., Alsrhani A., Zafar A., Javed H., Junaid K., Abdalla A. E., Abosalif K. O.A., Ahmed Z., Younas S. J. COVID-19 and comorbidities: Deleterious impact on infected patients. Infect Public Health. 2020; 13(12): 1833–1839. doi: 10.1016/j.jiph.2020.07.014. Epub 2020 Aug 4.
7. Silaghi-Dumitrescu R., Patrascu I., Lehene M., Bercea I. Comorbidities of COVID-19 Patients. Medicina (Kaunas). 2023; 59(8): 1393. doi: 10.3390/medicina59081393.
8. Vago J., Tavares L., Riccardi C., Teixeira M., Lirlândia P. S. Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseases. Biomedicine & Pharmacotherapy. 2021; 133:111033. doi: 10.1016/j.biopha.2020.111033.
9. Ampomah P., Kong W., Zharkova O., Chua S., Samy R., Lim L. Annexins in influenza virus replication and pathogenesis / Frontiers in Pharmacology. 2018; 15(9): 1282. doi: 10.3389/fphar.2018.01282. eCollection 2018.
10. D’Arcy M. S. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell biology international. 2019; 43(6): 582–592.
11. Kupcho K., Shultz J., Hurst R., Hartnett J., Zhou W., Machleidt Т., Grailer J., Worzella Т., Riss Т., Lazar D., Cali J., Niles А. A real-time, bioluminescent annexin V assay for the assessment of apoptosis. Apoptosis. 2019; 24(1): 184–197.
12. Patil P., Shetty P., Patil Р., Shetty Р., Kuriakose N., Gollapalli Р., Shetty S., Bhandary R., Vishwanatha J., Ghate S. Molecular Insights on the Possible Role of Annexin A2 in COVID-19 Pathogenesis and Post-Infection Complications. International journal of molecular sciences. 2021; 22(20): 11028. doi: 10.3390/ijms222011028.
13. Canacik O., Sabirli R., Altintas E., Karsli E., Karis D., Kaymaz В., Tukenmez S., Kurt Ö., Koseler А. Annexin A1 as a potential prognostic biomarker for COVID-19 disease: Case–control study. International Journal of Clinical Practice. 2021; 75(10): e14606. doi: 10.1111/ijcp.14606. Epub 2021 Jul 14.
Review
For citations:
Kurmaeva A.Sh., Prokofieva T.V., Polunina O.S., Polunina E.A. Effect of comorbid pathology and its nosologic forms on annexin A5 levels in patients with SARS-COV-2-associated viral pneumonia. Medical alphabet. 2024;(4):60-63. (In Russ.) https://doi.org/10.33667/2078-5631-2024-4-60-63
Views:
69
Email this article 